Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Centre
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Investor Newsletters
Communication
In the News
Presentations
Contact Us
Contact Us
Email Alerts
In the news
Recent Posts
Amplia Enters into Preclinical Collaboration with Korean Specialist Drug Screening Company Next&Bio
Interim Data from ACCENT Pancreatic Cancer Trial
Dr Chris Burns elected as a Fellow to the Australian Academy of Health and Medical Sciences (AAHMS)
ASX Briefs podcast | Interview with Dr Chris Burns
Recruitment Restarts in Accent Pancreatic Cancer Trial
NBN News Interview
Categories
Archive
Company News
Investor Newsletters
Videos
29 May 2023
AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer
Read More
22 May 2023
PROACTIVE INTERVIEW | Dr Chris Burns discusses Amplia's collaboration with CSIRO
Read More
22 May 2023
Amplia receives grant to collaborate with CSIRO
Read More
09 May 2023
Enrolment of Cohort 3 of ACCENT Trial in Pancreatic Cancer Complete
Read More
1
